Jiet Bio (688026.SH): Cumulatively repurchased 1.8194 million shares of the company's stock

Gelonghui, May 19 — JET BioPharma (SHA: 688026) announced that, as of the date of this announcement, the company has completed its share repurchase program. Through the centralized bidding trading system of the Shanghai Stock Exchange, the company has cumulatively repurchased 1,819,400 shares, representing 1.30% of its total share capital of 140,364,427 shares. The highest repurchase price was RMB 18.43 per share, the lowest was RMB 14.71 per share, and the average repurchase price was RMB 16.49 per share, with a total amount of funds used of RMB 29,997,583.36 (excluding transaction fees).

Gelonghui FinanceMay 19 18:28

Jet Bio-Technology (688026.SH): The company has repurchased 1.4201 million of its own shares.

Gelonghui, May 14 — Jiete Bio (688026.SH) announced that, as of May 13, 2026, the company has repurchased 1.4201 million shares through the Shanghai Stock Exchange's centralized bidding trading system, representing 1.01% of the company's current total share capital. The highest price paid per share was RMB 18.43, the lowest was RMB 14.71, and the total amount disbursed amounted to RMB 23.6014 million, excluding transaction commissions and other fees.

Gelonghui FinanceMay 14 15:38

Jiete Biotech's net profit attributable to shareholders in 2025 was RMB 48.2363 million, a year-on-year decrease of 36.23%. Revenue from overseas markets accounted for 57.99% of total revenue, hitting a record high.

In 2025, the company's revenue increased slightly by 0.95% to RMB 564 million, but the net profit attributable to shareholders dropped by 36.23% year-over-year to RMB 48.24 million. The non-recurring net profit declined by 48.79%, primarily due to significant impairment charges from an equity-method investment and rising expenses. The fourth quarter recorded a standalone loss, reflecting notable pressure on the core business. Meanwhile, net cash flow reached RMB 192 million, surging by 255.43% year-over-year, highlighting a divergence between cash generation and profitability that underscores quality discrepancies. Overseas revenue accounted for 57.99% of total income, with increased investments in both R&D and sales as the company accelerates its international expansion and new product portfolio development.

lanjinger.comApr 30 16:55

Jet Biochemical (688026.SH): Cumulative repurchase of 1.3015 million company shares

Gelonghui, April 30th - Jiete Biotech (688026.SH) announced that as of April 30, 2026, the company has repurchased 1.3015 million shares through the Shanghai Stock Exchange system via centralized bidding, accounting for 0.93% of the company’s current total share capital of 140,364,427 shares. The highest purchase price was 18.43 yuan per share, and the lowest was 14.71 yuan per share, with a total payment amounting to 21.6814 million yuan (excluding transaction commissions and other fees).

Gelonghui FinanceApr 30 15:48

Jet Bio: 2025 Annual Report

SZSIApr 30 00:00 · Announcements

Jiet Bio: First Quarter Report for 2026

SZSIApr 30 00:00 · Announcements